Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Enveric Biosciences

< Previous 1 2 Next >
Enveric Biosciences Announces Reverse Stock Split
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences to Explore Digital Asset Treasury Opportunities
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces Participation in 2025 BIO International Convention
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences CEO Issues Letter to Shareholders
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces Broad Range of Patent Issuances
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003
From Enveric Biosciences
Via Business Wire
Tickers ENVB
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.